IIT Bombay-Osmania Hospital Research Finds Biomarkers To Spot Early Signs Of Diabetic Kidney Disease
In a significant advancement in medical research, a team from the Indian Institute of Technology (IIT) Bombay, in collaboration with Osmania General Hospital in Hyderabad, has discovered specific biomarkers that can help identify early signs of kidney disease in diabetic patients. This breakthrough could allow for earlier intervention and better management of diabetic kidney disease (DKD).
Research Overview
The study, led by Professor Pramod Wangikar from IIT Bombay and Dr. Rakesh Kumar Sahay along with Dr. Manisha Sahay from Osmania Medical College, utilized metabolomics—the study of small molecules in the blood—to uncover biochemical patterns that indicate the risk of kidney complications in diabetes patients. The research team also collaborated with Clarity Bio Systems India, based in Pune.
Methodology
The researchers collected blood samples from a total of 52 volunteers between June 2021 and July 2022. The sample group consisted of:
- 15 healthy controls
- 23 patients with Type 2 diabetes
- 14 patients diagnosed with diabetic kidney disease
To analyze the blood samples, the team employed two advanced techniques: liquid chromatography-mass spectrometry (LC-MS) and gas chromatography-mass spectrometry (GC-MS). These methods allowed them to scan nearly 300 metabolites present in the blood.
Key Findings
Through their analysis, the researchers identified 26 metabolic products that displayed significant differences between diabetic patients and healthy controls. According to Sneha Rana, a PhD scholar in Professor Wangikar’s lab, “Type 2 diabetes is not just about high blood sugar. It disrupts amino acids, fats, and other pathways in the body. Standard tests often miss this hidden activity, which may often begin years before the onset of clinical symptoms.”
Implications of Biomarkers
The identified biomarkers have the potential to serve as early indicators of kidney complications in diabetic patients. This early detection can empower healthcare providers to recommend preventive measures and timely treatments, ultimately improving patient outcomes. The research team noted that seven of the metabolites they identified tend to increase progressively in diabetic patients, indicating a rising risk of kidney damage.
Expert Opinions
Dr. Rakesh Kumar Sahay emphasized the significance of these findings, stating, “Just as cholesterol tests help assess the risk of heart disease, these biomarkers could, in the future, be used to predict kidney disease in diabetics.” He further added, “Early identification of such biomarkers can significantly improve disease management and reduce the burden of kidney disease in India.”
Public Health Context
India is often referred to as the diabetes capital of the world, with approximately 101 million adults currently living with diabetes and an additional 136 million at risk of developing prediabetes. This alarming statistic highlights the urgent need for effective strategies to manage and mitigate the complications associated with diabetes, particularly diabetic kidney disease.
Conclusion
The research conducted by IIT Bombay and Osmania General Hospital marks a pivotal step forward in the early detection of diabetic kidney disease. By identifying specific biomarkers in the blood, healthcare professionals may soon be able to intervene before significant kidney damage occurs, improving the quality of life for millions of diabetic patients in India and beyond.
Note: The findings of this research are expected to pave the way for new diagnostic tools and treatment strategies that can enhance the management of diabetic kidney disease, ultimately contributing to better health outcomes for individuals affected by diabetes.
